Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1842 - Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Jianfeng Zhou

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

J. Zhou1, C. Bai2, Z. Sun2, Y. Cheng2, N. JIA3, Y. Zhou2

Author affiliations

  • 1 Department Of Medical Oncology, PUMCH, 100000 - Beijing/CN
  • 2 Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730 - Beijing/CN
  • 3 Medical Oncology, PUMCH, Beijing/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1842

Background

Early biomarkers of therapeutic responses could help optimize the treatment of metastatic colorectal cancer (mCRC). This prospective exploratory study was designed to explore the serial changes in plasma-circulating tumor DNA (ctDNA) as an early marker of therapeutic response to systemic treatment in mCRC.

Methods

Forty-seven mCRC patients receiving standard first-line therapy every two weeks were enrolled. Somatic mutations in plasma ctDNA were detected serially before each of the first four cycles via next-generation sequencing, and the mutation of maximal frequency in pretreatment ctDNA was selected as the candidate mutation for analysis. Radiologic responses were assessed after the fourth cycle.

Results

The results indicated that mutations in pretreatment ctDNA could be detected in 45 (95.7%) patients. Among the 41 patients monitored serially, imaging after four cycles of treatment showed 17 PR, 18 SD, and 6 PD cases. Changes in ctDNA could differentiate patients with progressive disease two cycles (approximately four weeks) earlier than the changes in CEA and CA19-9 levels could, and changes in ctDNA levels as early as prior to cycle 2 predicted the radiologic responses after cycle 4. A log2 value of fold-change in ctDNA after cycle 1 (log2 (C1/C0)) > -0.832 predicted progressive disease, with a sensitivity and specificity of 100.0% (95%CI: 54.1-100.0%) cand 85.7% (95%CI: 69.7-95.2%), respectively, and an accuracy of 87.8% (95%CI: 73.8-95.9%). Patients with ctDNA log2 (C1/C0) > -0.832 showed significantly worse progression-free survival than did those with log2 (C1/C0) ≤ -0.832 (median 2.5 versus 9.0 months; P = 0.016).

Conclusions

The present exploratory study suggests that early changes in ctDNA that are detected via targeted sequencing might potentially predict later radiologic responses in mCRC.

Clinical trial identification

Legal entity responsible for the study

Peking Union Medical College Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.